in the chemoprevention of breast cancer [1]. However, other than women with a prior diagnosis of atypical hyperplasia, in situ or invasive cancer, itThe current National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) trial with an endpoint of cancer incidence...